Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
Saved in:
| Title: | Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners. |
|---|---|
| Authors: | Doshi AS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cantin S; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hernandez M; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Srinivasan S; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Tentarelli S; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Griffin M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wang Y; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Pop-Damkov P; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Prickett LB; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Kankkonen C; Discovery Sciences, R&D, AstraZeneca, Mölndal, Sweden., Shen M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Martin MS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wu S; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Castaldi MP; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts., Ghadially H; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Varnes J; Global Portfolio and Project Management, Waltham, Massachusetts., Gales S; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Henry D; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Hoover C; Safety Pathology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Mele DA; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Simpson I; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Mlynarski SN; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Finlay MRV; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Drew L; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Shao W; Projects, Oncology R&D, AstraZeneca, Boston, Massachusetts., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 630-645. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
